Drug Approval | July 24, 2024
Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Accelerating sustainability in Indian pharma industry
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Submission based on results from pivotal phase III trial showing all primary endpoints met
Subscribe To Our Newsletter & Stay Updated
